MARKET

AUPH

AUPH

Aurinia Pharmace
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.99
-0.22
-2.15%
Opening 09:57 06/29 EDT
OPEN
10.20
PREV CLOSE
10.21
HIGH
10.21
LOW
9.88
VOLUME
151.93K
TURNOVER
845.58K
52 WEEK HIGH
33.97
52 WEEK LOW
8.86
MARKET CAP
1.42B
P/E (TTM)
-7.8439
1D
5D
1M
3M
1Y
5Y
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VICTORIA, British Columbia, June 06, 2022--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 06/06 20:05
Clover Health, Aurinia Pharma among the top 10 health care additions to Russell 3000 Index, Asensus Surgical, Clovis Oncology among top deletions
At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging
Seekingalpha · 06/06 15:39
BRIEF-Aurinia Presents Data Demonstrating Lupkynis® Is Effective In Achieving Proteinuria Treatment Targets In Lupus Nephritis Defined By Eular/Era Recommendations
reuters.com · 06/03 11:14
Aurinia Presented Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Aurinia Pharmaceuticals Inc.
Benzinga · 06/03 11:07
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.
Benzinga · 05/30 18:03
Aurinia Pharmaceuticals touts long-term benefit of Lupkynis for lupus
Aurinia Pharmaceuticals (NASDAQ:AUPH) said that data from a study showed that its lupus nephritis treatment Lupkynis (voclosporin) led to preservation of kidney function over three years of treatment. The AURORA
Seekingalpha · 05/20 16:32
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
VICTORIA, British Columbia, May 20, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today presented for the first time...
Business Wire · 05/20 16:07
Aurinia Pharmaceuticals Says Kidney Inflammation Treatment Continuation Study Shows Safety, Tolerability
MT Newswires · 05/20 13:21
More
No Data
Learn about the latest financial forecast of AUPH. Analyze the recent business situations of Aurinia Pharmace through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AUPH stock price target is 23.81 with a high estimate of 30.00 and a low estimate of 15.00.
High30.00
Average23.81
Low15.00
Current 10.08
EPS
Actual
Estimate
-0.31-0.23-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 224
Institutional Holdings: 49.64M
% Owned: 35.02%
Shares Outstanding: 141.74M
TypeInstitutionsShares
Increased
66
6.15M
New
33
6.92M
Decreased
44
4.53M
Sold Out
38
4.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.43%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
George Milne
President/Chief Executive Officer/Director
Peter Greenleaf
Chief Financial Officer
Joe Miller
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Stephen Robertson
Executive Vice President
Matthew Donley
Executive Vice President
Robert Huizinga
Chief Marketing Officer
Neil Solomons
Other
Massimiliano Colao
Other
Michael Martin
Director
Brinda Balakrishnan
Director
Daniel Billen
Independent Director
Joseph Hagan
Independent Director
David Jayne
Independent Director
Jill Leversage
Independent Director
R. Hector MacKay-Dunn
Independent Director
Timothy Walbert
No Data
No Data
About AUPH
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.